Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
Shuttle Pharmaceuticals, a specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy, has announced the issuance of U.S. Patent No. 12,077,515 for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease. The patent, issued on September 3, 2024, covers a series of selective HDAC inhibitors designed to modulate gene expression involved in cancer progression and immune responses.
This patent strengthens Shuttle Pharma's intellectual property portfolio, supporting its efforts to develop novel therapeutics targeting histone deacetylase (HDAC) enzymes. The company's HDAC platform aims to develop cancer immunotherapies and has potential applications in autoimmune, inflammatory, metabolic, neurological, and infectious diseases. Shuttle Pharma now holds over 20 composition of matter HDAC inhibitor patents in the U.S., Canada, and Europe.
Shuttle Pharmaceuticals, un'azienda farmaceutica specializzata concentrata sul miglioramento degli esiti per i pazienti affetti da cancro sottoposti a terapia radiativa, ha annunciato l'emissione del Brevetto Statunitense N. 12,077,515 per Inibitori Selettivi delle Istone Deacetilasi per il Trattamento delle Malattie Umane. Il brevetto, rilasciato il 3 settembre 2024, copre una serie di inibitori HDAC selettivi progettati per modulare l'espressione genica coinvolta nella progressione del cancro e nelle risposte immunitarie.
Questo brevetto rafforza il portafoglio di proprietà intellettuale di Shuttle Pharma, sostenendo i suoi sforzi per sviluppare nuovi farmaci terapeutici mirati agli enzimi delle istone deacetilasi (HDAC). La piattaforma HDAC dell'azienda punta a sviluppare immunoterapie oncologiche e ha potenziali applicazioni in malattie autoimmuni, infiammatorie, metaboliche, neurologiche e infettive. Shuttle Pharma detiene ora oltre 20 brevetti per composizioni di inibitori HDAC negli Stati Uniti, in Canada e in Europa.
Shuttle Pharmaceuticals, una empresa farmacéutica especializada centrada en mejorar los resultados de los pacientes con cáncer tratados con terapia de radiación, ha anunciado la emisión de Patente de EE. UU. N.º 12,077,515 para Inhibidores Selectivos de Histona Deacetilasa para el Tratamiento de Enfermedades Humanas. La patente, emitida el 3 de septiembre de 2024, cubre una serie de inhibidores HDAC selectivos diseñados para modular la expresión génica involucrada en la progresión del cáncer y las respuestas inmunitarias.
Esta patente fortalece la cartera de propiedad intelectual de Shuttle Pharma, apoyando sus esfuerzos para desarrollar terapias novedosas dirigidas a las enzimas de histona deacetilasa (HDAC). La plataforma HDAC de la compañía tiene como objetivo desarrollar inmunoterapias contra el cáncer y tiene aplicaciones potenciales en enfermedades autoinmunes, inflamatorias, metabólicas, neurológicas e infecciosas. Shuttle Pharma ahora posee más de 20 patentes de composición de materia de inhibidores HDAC en EE. UU., Canadá y Europa.
셔틀 제약(Shuttle Pharmaceuticals)은 방사선 치료를 받는 암환자의 치료 결과를 개선하는 데 중점을 둔 전문 제약 회사로, 미국 특허 제 12,077,515호를 선택적 히스톤 탈아세틸화 효소 억제제에 대해 발표했습니다. 이 특허는 2024년 9월 3일에 발행되었으며, 암의 진행 및 면역 반응에 관련된 유전자 발현을 조절하도록 설계된 일련의 선택적 HDAC 억제제를 포함하고 있습니다.
이 특허는 셔틀 제약의 지식재산권 포트폴리오를 강화하여 히스톤 탈아세틸화 효소(HDAC)를 표적으로 하는 새로운 치료제를 개발하는 노력을 지원합니다. 회사의 HDAC 플랫폼은 암 면역 요법을 개발하는 것을 목표로 하며, 자가면역, 염증, 대사, 신경 및 감염 질환에 대한 잠재적 응용 가능성을 가지고 있습니다. 셔틀 제약은 현재 미국, 캐나다 및 유럽에서 20개 이상의 HDAC 억제제 물질 특허를 보유하고 있습니다.
Shuttle Pharmaceuticals, une entreprise pharmaceutique spécialisée axée sur l'amélioration des résultats pour les patients atteints de cancer traités par radiothérapie, a annoncé l'émission du Brevet américain N° 12,077,515 pour des Inhibiteurs sélectifs des histones déacétylases pour le traitement des maladies humaines. Le brevet, délivré le 3 septembre 2024, couvre une série d'inhibiteurs HDAC sélectifs conçus pour moduler l'expression génétique impliquée dans la progression du cancer et les réponses immunitaires.
Ce brevet renforce le portefeuille de propriété intellectuelle de Shuttle Pharma, soutenant ses efforts pour développer de nouveaux traitements ciblant les enzymes histones déacétylases (HDAC). La plateforme HDAC de l'entreprise vise à développer des immunothérapies contre le cancer et a des applications potentielles dans les maladies auto-immunes, inflammatoires, métaboliques, neurologiques et infectieuses. Shuttle Pharma détient maintenant plus de 20 brevets de composition de matières pour les inhibiteurs HDAC aux États-Unis, au Canada et en Europe.
Shuttle Pharmaceuticals, ein spezialisiertes Pharmaunternehmen, das sich darauf konzentriert, die Ergebnisse für Krebspatienten, die mit Strahlentherapie behandelt werden, zu verbessern, hat die Erteilung von US-Patent Nr. 12,077,515 für Selektive Histon-Deacetylase-Inhibitoren zur Behandlung menschlicher Erkrankungen bekannt gegeben. Das Patent, das am 3. September 2024 erteilt wurde, umfasst eine Reihe selektiver HDAC-Inhibitoren, die entwickelt wurden, um die Genexpression zu modulieren, die an der Krebsprogression und den Immunantworten beteiligt ist.
Dieses Patent stärkt das geistige Eigentum-Portfolio von Shuttle Pharma und unterstützt die Bemühungen, neuartige Therapeutika zu entwickeln, die auf Histon-Deacetylase (HDAC)-Enzyme abzielen. Die HDAC-Plattform des Unternehmens zielt darauf ab, Immuntherapien gegen Krebs zu entwickeln und hat potenzielle Anwendungen bei autoimmunen, entzündlichen, metabolischen, neurologischen und infektiösen Krankheiten. Shuttle Pharma hält nun über 20 Patente für die Zusammensetzung von HDAC-Inhibitoren in den USA, Kanada und Europa.
- Issuance of U.S. Patent No. 12,077,515 for Selective Histone Deacetylase Inhibitors
- Strengthened intellectual property portfolio with over 20 HDAC inhibitor patents in U.S., Canada, and Europe
- Potential applications of HDAC platform beyond cancer, including autoimmune and inflammatory diseases
- None.
Insights
The issuance of U.S. Patent No. 12,077,515 for selective HDAC inhibitors is a significant milestone for Shuttle Pharmaceuticals. This patent strengthens their intellectual property portfolio and protects their novel approach to cancer treatment. The focus on HDAC6 inhibition for regulating innate immune responses to irradiated cancer cells is particularly innovative.
However, it's important to note that while patent issuance is promising, it doesn't guarantee commercial success. The
Shuttle Pharma's focus on developing radiation sensitizers is addressing a crucial need in cancer treatment. By potentially enhancing the effectiveness of radiation therapy while mitigating side effects, their approach could significantly improve patient outcomes. The company's strategy of targeting HDAC6 for immune response regulation is particularly intriguing, as it aligns with the growing interest in immuno-oncology.
However, investors should be aware that the path from patent to approved therapy is long and costly. While this patent is promising, Shuttle Pharma will need to demonstrate clinical efficacy and safety in human trials before their approach can be considered a true breakthrough in cancer treatment.
This patent issuance strengthens Shuttle Pharma's position in the competitive oncology market. The company's focus on improving radiation therapy outcomes addresses a significant market need, given that approximately
However, as a discovery and development stage company, Shuttle Pharma faces significant financial and regulatory hurdles. Investors should closely monitor the company's cash burn rate, clinical trial progress and potential partnerships or licensing deals. The transition from preclinical to clinical stages will be important for the company's valuation and long-term prospects.
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the issuance of U.S. Patent No. 12,077,515, titled “Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease.” This patent was officially issued on September 3, 2024, further strengthening Shuttle Pharma’s intellectual property portfolio and supporting its ongoing efforts to develop novel therapeutics targeting histone deacetylase (HDAC) enzymes.
The newly issued patent covers a series of selective HDAC inhibitors designed to modulate the expression of genes involved in cancer progression, immune responses, and other critical biological pathways. These inhibitors are being developed as potential treatments for a range of human diseases, including cancer.
Shuttle Pharma’s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle Pharma has deployed its proprietary technology to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications. Shuttle Pharma’s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including autoimmune, inflammatory, metabolic, neurological and infectious diseases.
“We are excited to receive this patent, which reflects our commitment to pioneering therapies that address significant unmet medical needs,” said Anatoly Dritschilo, MD, CEO of Shuttle Pharmaceuticals. “These drug candidates were invented by Shuttle Pharma's scientists based on our strategy to selectively inhibit HDAC6 for regulation of the innate immune response to irradiated cancer cells. This achievement underscores Shuttle Pharmaceuticals' role at the forefront of innovative drug development and positions us for further advances in our clinical pipeline.”
Shuttle Pharma now holds more than 20 composition of matter HDAC inhibitor patents in the U.S., Canada and Europe.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements concerning the development of our company. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2023, as amended, filed with the SEC on September 4, 2024, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
FAQ
What is the new patent issued to Shuttle Pharmaceuticals (SHPH) for?
How many HDAC inhibitor patents does Shuttle Pharma (SHPH) now hold?
What is the main focus of Shuttle Pharmaceuticals (SHPH)?
What potential applications does Shuttle Pharma's (SHPH) HDAC platform have beyond cancer?
